VeonGen Therapeutics Rebrands and Advances Gene Therapy for Stargardt Disease

VeonGen Therapeutics, previously known as ViGeneron, has announced its rebranding and marked significant clinical progress with its gene therapy VG801 for Stargardt disease. This therapy received the Rare Pediatric Disease Designation from the FDA, emphasizing its potential in treating ABCA4 mutation-associated retinal dystrophy. VG801 is currently in a first-in-human Phase 1/2 trial, showcasing VeonGen's commitment to addressing unmet medical needs in ophthalmology.

The company is leveraging its vgRNA REVeRT and vgAAV technology platforms to develop groundbreaking gene therapies. Besides VG801, VeonGen is advancing another therapy, VG901, targeting retinitis pigmentosa. These efforts position VeonGen as a key player in genetic medicine, with potential expansions in cardiovascular and CNS disease areas.